SCHEMBL2961146

SCHEMBL2961146

O=C1C[C@@H](c2ccc(O)c(OC3OC(CO)C(O)C(O)C3O)c2)Oc2cc(OC3OC(CO)C(O)C(O)C3O)ccc21

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 1/20 0.75
▸ P4HB P07237 1/20 0.75
▸ TRPV1 Q8NER1 1/20 0.75
▸ SLCO2B1 O94956 2/20 0.68
▸ SYNJ2 O15056 1/20 0.68
▸ PTPN1 P18031 4/20 0.65
▸ KDM1A O60341 2/20 0.63
▸ CYP19A1 P11511 5/20 0.58
▸ RELA Q04206 1/20 0.57
▸ PKM P14618 1/20 0.55
▸ GSK3B P49841 2/20 0.53
▸ UBE2N P61088 1/20 0.53
▸ DPP4 P27487 1/20 0.52
▸ XDH P47989 1/20 0.51
▸ POLB P06746 1/20 0.49
▸ CALM1 P0DP23 1/20 0.49
▸ CACNA1B Q00975 1/20 0.49
▸ APBA1 Q02410 1/20 0.49
▸ CTDSP1 Q9GZU7 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22261653 0.94 SLCO2B1 (0.77) TRPA1P4HBTRPV1SLCO2B1SYNJ2
SCHEMBL22380698 0.94 SLCO2B1 (0.77) TRPA1P4HBTRPV1SLCO2B1SYNJ2
SCHEMBL29351306 0.90 TRPA1 (0.89) TRPA1P4HBTRPV1SLCO2B1SYNJ2
SCHEMBL31504735 0.88 TRPA1 (0.79) TRPA1P4HBTRPV1SLCO2B1SYNJ2
SCHEMBL27939664 0.88 TRPA1 (0.79) TRPA1P4HBTRPV1SLCO2B1SYNJ2
SCHEMBL10926327 0.88 TRPA1 (0.79) TRPA1P4HBTRPV1SLCO2B1SYNJ2
Liquiritin SCHEMBL24209243 0.86 TRPA1 (1.00) TRPA1P4HBTRPV1SLCO2B1SYNJ2
Liquiritin SCHEMBL29536850 0.86 TRPA1 (1.00) TRPA1P4HBTRPV1SLCO2B1SYNJ2
Liquiritin SCHEMBL24835038 0.86 TRPA1 (1.00) TRPA1P4HBTRPV1SLCO2B1SYNJ2
Liquiritin SCHEMBL13906116 0.86 TRPA1 (1.00) TRPA1P4HBTRPV1SLCO2B1SYNJ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 — — WO claimed
US-11234918-B2 Methods for botanical and/or algae extraction BASF CORPORATION (US) 2022-02-01 — — US claimed
WO-2020244249-A1 APPLICATION OF COMPOSITION CONTAINING NICOTINAMIDE MONONUCLEOTIDE IN ANTI-AGEING DRUGS/HEALTHCARE PRODUCTS 泓博元生命科技(深圳)有限公司 2020-12-10 — — WO claimed
US-9775797-B2 Personal care composition CONOPCO, INC. (US) 2017-10-03 — — US claimed
EP-2858641-B1 IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF CORP (US) 2017-09-06 — — EP claimed
CN-104302361-B A personal care composition 荷兰联合利华有限公司 2017-05-24 — — CN claimed
US-20150140141-A1 METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) 2015-05-21 — — US claimed
EP-2858641-A1 IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF Corporation (US) 2015-04-15 — — EP claimed
EP-2833976-A1 A PERSONAL CARE COMPOSITION Unilever N.V. (NL) 2015-02-11 — — EP claimed
US-20150037267-A1 PERSONAL CARE COMPOSITION Conopco., Inc., d/b/a UNILEVER (US) 2015-02-05 — — US claimed
CN-104188997-A Application of butriptyline in preparing liver protection medicine NANJING ZELANG MEDICAL TECH CO 2014-12-10 — — CN claimed
WO-2013184884-A1 IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION BASF CORPORATION (US) 2013-12-12 — — WO claimed
WO-2013149791-A1 A PERSONAL CARE COMPOSITION UNILEVER N.V. (NL) 2013-10-10 — — WO claimed
CN-103265592-A Extracting and purifying method of butrin NANJING ZELANG MEDICAL TECH CO 2013-08-28 — — CN claimed
CN-102875618-A Purifying method of butrin NANJING ZELANG AGRI DEV CO LTD 2013-01-16 — — CN claimed
CN-101287481-A A pharmaceutical composition useful for the treatment of hepatocellular carcinoma COUNCIL SCIENT IND RES (IN) 2008-10-15 — — CN claimed
EP-1883453-A1 A PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-02-06 — — EP claimed
US-20060280817-A1 Pharmaceutical composition useful for the treatment of hepatocellular carcinoma COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-12-14 — — US claimed
WO-2006126067-A1 A PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-11-30 — — WO claimed
WO-2006111251-A2 HYDRO-ALCOHOLIC EXTRACT OF BUTEA FRONDOSA FLOWERS, A PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND ITS USE FOR THE TREATMENT OF ULCER INDENA S.P.A. (IT) 2006-10-26 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11234918-B2 Methods for botanical and/or algae extraction ALG1, ALG8, CUTA TRPA1 2889/4885P4HB 3427/4885TRPV1 2708/4885
US-20150037267-A1 PERSONAL CARE COMPOSITION CUTA, KRT18, PSAP TRPA1 2029/4885P4HB 592/4885TRPV1 2594/4885
US-20150140141-A1 METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION ALG1, ALG8, CUTA TRPA1 2889/4885P4HB 3427/4885TRPV1 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback